Showing 81 - 100 results of 8,839 for search '(( significant ((changes decrease) OR (larger decrease)) ) OR ( significant processes decrease ))', query time: 0.44s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84
  5. 85

    Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  6. 86

    Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  7. 87
  8. 88
  9. 89

    Fig 11 - by Naveed Arshad (19712985)

    Published 2024
    Subjects:
  10. 90
  11. 91
  12. 92
  13. 93

    Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  14. 94

    Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  15. 95

    Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  16. 96

    Change in the genotypes of <i>ATM</i>, <i>ERCC1</i>, and <i>XRCC1</i>. by Hao Deng (409186)

    Published 2024
    “…AA (OR = 3.016) and CA (OR = 2.130) genotypes were identified as risk factors for stage II. ERCC1 significantly decreased in processing of CWP. The cutoff value of ERCC1 was 5.265 pg/ml, with a sensitivity of 90.0% and specificity of 86.7%. …”
  17. 97
  18. 98
  19. 99
  20. 100